Global Mpox Outbreak: A Wake-Up Call for Vaccine Research in Africa

The 2022-2023 global mpox outbreak wasn’t just a health crisis; it was a profound wake-up call for the world, especially when it comes to vaccine research in Africa. For the first time since 1970, mpox clade II crossed its traditional borders, causing sustained transmission outside Africa. This outbreak exposed significant gaps in global health preparedness and highlighted the urgent need for more focused research and vaccine development in Africa.

As the outbreak spread globally, efforts to contain mpox escalated in high-income countries. However, this same sense of urgency has not been mirrored for the endemic mpox burden in Africa, where clade I continues to circulate. Recently, the Democratic Republic of the Congo (DRC) has been battling an increase in clade I cases, with new evidence suggesting sexual transmission—a worrying indication that the virus could spread further across the globe.

Addressing Research Gaps: The African Perspective

Despite the increased global focus on mpox, African researchers have faced significant funding challenges for years. Their calls for investment in diagnostic tools, therapeutic interventions, and infection prevention strategies were largely ignored until the outbreak affected wealthier nations. The rapid global response to mpox outbreaks demonstrates that concerted efforts can control the virus—but sustaining this progress requires continued investment in research to understand the unique epidemiological patterns of mpox in Africa.

CRK Clinical Research Key (CRO) is actively involved in promoting vaccine studies and clinical trials in Africa. With our base in Kenya, we recognize the urgent need to invest in research efforts that address the unique challenges faced by African populations in combating mpox. We are committed to advocating for African-led mpox research, particularly in areas such as:

• Vaccine Development: Understanding the effectiveness of existing vaccines in African contexts and developing new, targeted vaccines.
• Transmission Patterns: Investigating the novel modes of transmission, such as sexual contact, and how these impact public health strategies.
• Public Health Interventions: Creating effective preventive measures tailored to the local population and the socio-economic context of Africa.

A Call for Global Action

The global reduction in mpox cases following swift international intervention is proof that coordinated global health responses work. However, true global health security can only be achieved when Africa is safe. We must push for increased funding, collaborative research, and more vaccine trials that focus on Africa’s specific needs. By doing so, we will not only prevent future outbreaks but also ensure that health equity becomes a reality.

Join Us in Advocating for Vaccine Research in Africa

At CRK Clinical Research Key (CRO), we believe that no one is safe until Africa is safe. Join us in advocating for increased support for vaccine research and clinical trials that prioritize Africa’s needs. Let’s work together to close the gap in global health preparedness and ensure a safer future for all.